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ABSTRACT
Objectives: We aimed to examine longitudinally
whether workplace bullying was associated with
subsequent psychotropic medication among women
and men.
Design: A cohort study.
Setting: Helsinki, Finland.
Participants: Employees of the City of Helsinki,
Finland (n=6606, 80% women), 40–60 years at
baseline in 2000–2002, and a register-based follow-up
on medication.
Primary and secondary outcome measures:
Workplace bullying comprised questions about current
and earlier bullying as well as observing bullying. The
Finnish Social Insurance Institution’s register data on
purchases of prescribed reimbursed psychotropic
medication were linked with the survey data. All
psychotropic medication 3 years prior to and 5 years
after the baseline survey was included. Covariates
included age, prior psychotropic medication, childhood
bullying, occupational class, and body mass index. Cox
proportional hazard models (HR, 95% CI) were fitted
and days until the first purchase of prescribed
psychotropic medication after baseline were used as
the time axis.
Results: Workplace bullying was associated with
subsequent psychotropic medication after adjusting for
age and prior medication among both women (HR
1.51, 95% CI 1.18 to 1.93) and men (HR 2.15, 95% CI
1.36 to 3.41). Also observing bullying was associated
with subsequent psychotropic medication among
women (HR 1.53, 95% CI 1.25 to 1.88) and men
(HR 1.92, 95% CI 1.23 to 2.99). The associations only
modestly attenuated after full adjustment.
Conclusions: Our findings highlight the significance
of workplace bullying to subsequent psychotropic
medication reflecting medically confirmed mental
problems. Tackling workplace bullying likely helps
prevent mental problems among employees.
INTRODUCTION
Workplace bullying is a prevalent problem in
the workforce. In Finland, bullying affects
roughly 5–10% of employees.1 2 However,
the prevalence of bullying depends on its
ARTICLE SUMMARY
Article focus
▪ Workplace bullying is a prevalent problem, which
is associated with poorer mental health based on
some previous studies using self-reported
measures.
▪ There are no previous studies on workplace
bullying and psychotropic medication using lon-
gitudinal data and objectively measured, register-
based outcome.
▪ We hypothesised that workplace bullying is asso-
ciated with the risk of psychotropic medication
among both women and men, and that these
associations are found both for victims of bully-
ing and the observers. Moreover, we hypothe-
sised that the associations remain even after
considering key covariates.
Key messages
▪ This study showed that workplace bullying con-
tributes to the risk of subsequent psychotropic
medication among women and men who were
victims or observers of bullying at their work-
place. Also earlier exposures to bullying were
associated with psychotropic medication over the
5-year follow-up.
▪ The associations remained after prior psycho-
tropic medication, childhood bullying, occupa-
tional class and body mass index, had been
taken into account.
▪ These findings further suggest that tackling
workplace bullying helps prevent mental health
problems among employees.
Strengths and limitations of this study
▪ The strength of this study was the use of register
linkages. Thus, the data on medication were
objective and covered all reimbursed psycho-
tropic medication. Furthermore, we were able to
consider prior psychotropic medication 3 years
before the baseline, as well as had a 5-year
follow-up. The data were large and comprised
both women and men.
▪ A limitation of this study was that the measures
of bullying were based on single items and we
were unable to examine the duration and inten-
sity of bullying.
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deﬁnition and varies between workplaces and cohorts.3
Albeit there are differences in the deﬁnitions and mea-
sures of workplace bullying, similar phenomena are
likely captured. In general, workplace bullying is about
situations at work, where the victims are in an unequal
position with respect to their bully and are unable to
defend themselves against the negative actions.4 5 Such
workplace bullying also is systematic and typically persists
over longer periods of time.
Workplace bullying occurs in many different contexts,
and its forms can be either mental or even physical towards
the victim.4 6 As a consequence, bullying causes psycho-
social distress, but the victims of bullying also have a higher
risk of both mental and physical health problems.1 2 4
However, few longitudinal studies have been conducted,
and both bullying and its health-related consequences have
been self-reported. In a previous cross-sectional study in
France, associations between workplace bullying and self-
reported use of psychotropic medication such as sleep
medication, tranquilisers and medication for mental health
problems were reported.7 Furthermore, a dose–response
was suggested: the longer the exposure to bullying and the
higher its frequency, the stronger the associations. Also in
some other cross-sectional studies, similar associations
between workplace bullying and self-reported psychotropic
medication have been reported.1 8–10 Interpersonal
conﬂicts at work have even been associated with higher risk
of more severe mental disorders such as long-term psych-
osis and psychiatric hospital treatment in a prospective
Finnish study.11 Our previous prospective studies have
shown that workplace bullying at baseline is associated with
subsequent self-reported common mental disorders12 and
sleep problems13 at follow-up. Earlier prospective ﬁndings
suggest that victims of bullying also have a higher risk for
subsequent depression,2 mental distress14 and sickness
absence.15 All these previous studies highlight the adverse
consequences of bullying for employee health in general
and mental health in particular, as well as productivity at
workplaces.16 17
In addition to adverse consequences among the
bullied employees, cross-sectional studies have suggested
that even observers of bullying may be at risk of health
problems.1 7 18 Our previous prospective study included
observing bullying at workplace as an indicator of ‘work-
place climate’ alongside various psychosocial and other
working conditions.19 However, the study did not focus
on bullying, and the variable was treated as a dichotom-
ous one. Observing bullying was associated particularly
with antidepressant medication among men. Some pre-
vious studies also highlight the signiﬁcance of earlier
bullying to subsequent health,20 and even bullying in
childhood may contribute to bullying in adulthood.21
Our aim was to examine whether workplace bullying
at baseline is associated with subsequent psychotropic
medication reﬂecting medically conﬁrmed mental pro-
blems over the follow-up. Covariates, such as prior medi-
cation, occupational class, body mass index and
childhood bullying, were included for robust evidence
about the contribution of workplace bullying to subse-
quent psychotropic medication.2 7 15 21 Earlier studies
have been mainly cross-sectional or based on self-
reported mental health. Thus, using more objective
register-based psychotropic medication as outcome
allows conﬁrming the previous ﬁndings relying on
self-reports.
METHODS
Data
The baseline data were derived from the Helsinki
Health Study cohort mail questionnaire surveys among
40- to 60-year-old employees of the City of Helsinki,
Finland, in 2000–2002 (n=8960, response rate 67%).22
According to our non-response and attrition analyses,
the data are broadly representative of the target popula-
tion,22–24 except for men, younger participants, manual
workers and those with long sickness absence spells are
slightly over-represented among the non-respondents.
A ﬂow diagram of the study and further details of non-
response and attrition are reported elsewhere.22 The
City of Helsinki is the largest employer in Finland, and
there are around 200 different non-manual and manual
occupations.
Psychotropic medication
Psychotropic medication data were derived from the pre-
scription register of the Social Insurance Institution,
Finland. These data include all purchases of prescribed
reimbursed psychotropic medication, called psychotropic
medication for short. The Social Insurance Institution’s
register data on medication are classiﬁed according to
the WHO Anatomical Therapeutic Chemical classiﬁca-
tion.25 For the present study, all psychotropic medication
coded as N05 (psycholeptics) and N06 (psychoanalep-
tics) was included; medication for dementia (N06D) was
excluded. Prior psychotropic medication 3 years before
the baseline survey was adjusted for, as a covariate, and
the follow-up time after the baseline survey was 5 years or
the time until the ﬁrst purchase of psychotropic medica-
tion or death (censored).
The psychotropic medication data were linked with
the baseline survey data among those who had given an
informed written consent for such linkages (n=6606,
74%). In Finland, each resident has a unique personal
identiﬁcation number that can be used to such register
data linkages. After the exclusion of participants with
current psychotropic medication at baseline (n=319),
the data about eligible participants for this study
amounted to 6287. Owing to item non-response to cov-
ariates and workplace bullying (approximately 0.5–1.5%
per item), the ﬁnal data used in the analyses comprised
4681 women and 1315 men.
According to our earlier analyses, non-consenters to
data linkages were slightly younger, in lower socio-
economic positions and with more medically certiﬁed
sickness absence spells than consenters.22 23 On the
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basis of these analyses, the data are representative and
consenters and non-consenters to data linkages are
broadly similar.
Workplace bullying
We used two questions on workplace bullying in line
with previous studies.2 26 The questionnaires included
an instruction before the actual questions: “Mental vio-
lence or workplace bullying means isolation of a
member of the organisation, underestimation of work
performance, threatening, talking behind one’s back or
other pressurizing.”
First, the respondents were asked whether they had
been bullied in their current workplace, earlier in the
same or in another workplace, never or could not say.
Those who reported that they had never been bullied
formed a reference category in the analyses to whom
the other respondents were compared. A second ques-
tion asked about observing such behaviour at the
respondent’s workplace using four response alternatives:
not at all, sometimes, frequently or could not say. Those
who reported that they did not observe bullying at their
workplace were used as a reference category.
Covariates
Age was included as 5-year age groups. Register based
previous psychotropic medication 3 years before the
baseline survey was included as a covariate. Childhood
bullying reported at baseline was asked by a question
enquiring whether the participant had been bullied
before turning 16 years. Data about occupational classes
included manual workers, routine non-manual employ-
ees, semiprofessionals professionals and managers.
These data were derived from the employers’ personnel
registers and completed from the questionnaires for
those without consents to link questionnaire data with
the registers. Body mass index (BMI) was based on self-
reported height and weight at baseline, and was
included as a continuous variable.
Ethical approvals
Ethical approvals for the Helsinki Health Study have
been obtained from the ethics committees at the
Department of Public Health, University of Helsinki and
the City of Helsinki Health Authorities.
Statistical analyses
Descriptive statistics on the prevalence of bullying and
psychotropic medication among women and men were
calculated. A directed acyclic graph shows the assumed
causal associations between the key study variables
(ﬁgure 1). Cox proportional hazard models were ﬁtted
to examine the associations between workplace bullying
and subsequent psychotropic medication. Days until the
ﬁrst purchase after baseline were used as a time axis.
First, age was adjusted for in all the analyses (Model 1).
Second, all previous psychotropic medication 3 years
prior baseline survey was adjusted for in addition to age
(Model 2). All further covariates were added in Model 2.
Model 3 was adjusted for childhood bullying.
Occupational class was adjusted for in Model 4, and
Model 5 was adjusted for BMI. Model 6 was a full model
mutually adjusted for all covariates. The results are pre-
sented as HR and their 95% CI. The analyses were con-
ducted using SAS statistical programme V.9.2 (SAS
Institute Inc, Cary, North Carolina, USA), and R.27
RESULTS
Prevalence of workplace bullying and psychotropic
medication
Five per cent of women and men reported that they were
bullied at baseline (table 1). Additionally, 18% of women
and 12% of men reported earlier bullying in the same or
another workplace. Around half of women and men had,
at least sometimes, observed bullying at their workplace,
whereas 8% of women and 7% of men had frequently
observed bullying. Many respondents also reported that
they did not know if they had been bullied (10% of
women and 11% of men) or if they had observed bullying
(6% of women and 5% of men) at their workplace.
Psychotropic medication was more prevalent among
women than among men: 23% of women and 17% of
men had at least one purchase of prescribed, reim-
bursed psychotropic medication over the follow-up,
whereas 16% of women and 10% of men had psycho-
tropic medication 3 years prior baseline.
Associations of workplace bullying with psychotropic
medication
Workplace bullying was associated with subsequent psycho-
tropic medication (table 2). After adjusting for age, both
current (HR 1.72, 95% CI 1.34 to 2.19) and earlier bulling
(HR 1.56, 95% CI 1.35 to 1.80) were associated with
psychotropic medication among women (Model 1).
Adjustment for previous psychotropic medication
(Model 2) somewhat attenuated the associations, whereas
the effects of other covariates (Models 3–5) were negli-
gible. Thus, the effect sizes remained similar to Model 2.
Current (HR 1.48, 95% CI 1.16 to 1.89) and earlier (HR
1.29, CI 95% 1.11 to 1.50) bullying remained associated
with subsequent psychotropic medication even after full
adjustment (Model 6).
The associations among men were somewhat stronger
than among women. After adjusting for age, both current
(HR 2.75, 95% CI 1.75 to 4.33) and earlier bullying (HR
2.37, 95% CI 1.69 to 3.33) were associated with psycho-
tropic medication among men (Model 1). As among
women, the adjustment for previous psychotropic medi-
cation led to the strongest attenuation of the association
(Model 2), whereas the effects of other covariates were
negligible, and the HRs remained relatively similar to
Model 2. Both current (HR 1.93, 95% CI 1.20 to 3.10)
and earlier bullying (HR 1.71, 95% CI 1.21 to 2.44)
remained associated with psychotropic medication after
full adjustment among men (Model 6).
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Also observing bullying at workplace was associated
with psychotropic medication among women and men
(table 3). After adjusting for age (Model 1), frequently
observing bullying was associated with psychotropic medi-
cation among women (HR 1.78, 95% CI 1.45 to 2.18).
Previous psychotropic medication attenuated this associ-
ation (Model 2), whereas the effects of other covariates,
added in the model including age and previous psycho-
tropic medication, were negligible (Models 3–5). The
association remained after full adjustment (Model 6, HR
1.50, 95% CI 1.22 to 1.84).
Among men, after adjusting for age (Model 1), fre-
quently observing bullying was associated with psycho-
tropic medication (HR 2.32, 95% CI 1.49 to 3.61). The
association attenuated but remained after adjustments for
covariates (Models 2–5), and after full adjustment (Model
6, HR 1.65, 95% CI 1.04 to 2.60). Also sometimes observ-
ing bullying was associated with psychotropic medication
among men, but only in the age adjusted Model 1 (HR
1.38, 95% CI 1.02 to 1.86).
Further analyses separately examined antidepressant
medication, as well as sedatives and anxiolytic medica-
tion (data not shown). As the largest part of all psycho-
tropic medication was antidepressant medication, the
associations for any psychotropic medication broadly
reﬂected those for antidepressants. However, when only
antidepressant medication was examined, the associa-
tions were slightly stronger.
DISCUSSION
Principal findings
A particular aim of this study was to examine the associa-
tions of workplace bullying with mental health problems
using objective register data on psychotropic medication
in a longitudinal study design. First, overall, being
bullied was associated with psychotropic medication
among both women and men. This association
remained after considering previous psychotropic medi-
cation and several covariates. Second, even earlier bully-
ing was associated with subsequent psychotropic
medication among both women and men. Third, also
observing bullying at workplace was associated with psy-
chotropic medication, and the association remained
after considering the covariates. These ﬁndings conﬁrm
those from previous cross-sectional studies and, in par-
ticular, corroborate associations found between work-
place bullying and self-reported mental health.
Previous studies
Comparability to previous studies is limited, as most
studies have relied on cross-sectional designs and self-
reported medication. However, our results are in accord-
ance with those from an earlier cross-sectional study,
which reported an association between workplace bully-
ing and self-reported psychotropic medication among
French employees.7 Observing bullying was also asso-
ciated with psychotropic medication in that earlier study.
Some other, mainly cross-sectional, studies examining
the associations between workplace bullying or conﬂicts
at work with self-reported use of sleep-induced drugs,
tranquilisers, antidepressants and sedatives have also
shown similar associations with ours, suggesting adverse
consequences of earlier and current bullying or conﬂicts
at work for psychotropic medication.1 8–10 26 28 29
However, not all these studies have focused explicitly on
workplace bullying, and the measurement of psycho-
tropic medication has been limited and mainly based on
single self-reported items. Thus, mental health outcomes
Figure 1 A directed acyclic graph (DAG) of the assumed causal associations between the study variables.
Table 1 Distribution (%) of key study variables
Women
(n=4681) (%)
Men
(n=1315) (%)
Workplace bullying
No 67.3 71.8
Yes, currently 4.7 5.3
Earlier, in this or
another workplace
17.8 12.2
I do not know 10.3 10.7
Observing bullying at workplace
No 36.3 42.5
Sometimes 50.5 44.9
Frequently 7.7 7.2
I do not know 5.5 5.4
Any psychotropic
medication after baseline
23.3 16.5
Any prior psychotropic
medication
15.7 10.4
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Table 2 Workplace bullying at baseline and subsequent psychotropic medication (HR, and their 95% Confidence Intervals, 95% CI from Cox regression models)
Workplace
bullying
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Women (n=4681)
No 1.00 1.00 1.00 1.00 1.00 1.00
Yes, currently 1.72 (1.34 to 2.19) 1.51 (1.18 to 1.93) 1.49 (1.16 to 1.90) 1.50 (1.17 to 1.92) 1.51 (1.18 to 1.93) 1.48 (1.16 to 1.89)
Earlier, in this
or another
workplace
1.56 (1.35 to 1.80) 1.31 (1.13 to 1.51) 1.29 (1.11 to 1.49) 1.31 (1.13 to 1.52) 1.30 (1.13 to 1.51) 1.29 (1.11 to 1.50)
I do not know 1.30 (1.07 to 1.57) 1.23 (1.02 to 1.49) 1.21 (1.00 to 1.47) 1.23 (1.01 to 1.49) 1.23 (1.02 to 1.49) 1.21 (0.99 to 1.46)
Men (n=1315)
No 1.00 1.00 1.00 1.00 1.00 1.00
Yes, currently 2.75 (1.75 to 4.33) 2.15 (1.36 to 3.41) 1.94 (1.20 to 3.13) 2.21 (1.40 to 3.49) 2.18 (1.38 to 3.43) 1.93 (1.20 to 3.10)
Earlier, in this
or another
workplace
2.37 (1.69 to 3.33) 1.94 (1.38 to 2.74) 1.85 (1.30 to 2.62) 1.94 (1.38 to 2.73) 1.82 (1.29 to 2.58) 1.71 (1.21 to 2.44)
I do not know 1.52 (1.00 to 2.30) 1.26 (0.83 to 1.92) 1.25 (0.82 to 1.91) 1.29 (0.85 to 1.97) 1.23 (0.81 to 1.86) 1.23 (0.81 to 1.87)
Model 1, age adjusted for; Model 2, age and previous psychotropic medication adjusted for; Model 3, age, previous psychotropic medication and childhood bullying adjusted for; Model 4, age,
previous psychotropic medication and occupational class adjusted for; Model 5, age, previous psychotropic medication and body mass index adjusted for; and Model 6, all variables in Models
1–5 adjusted for (full model).
Table 3 Observing bullying at workplace at baseline and subsequent psychotropic medication (HR, and their 95% CIs, 95% Confidence Intervals from Cox regression
models)
Observing
bullying at
workplace
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Women (n=4681)
No 1.00 1.00 1.00 1.00 1.00 1.00
Sometimes 1.07 (0.94 to 1.22) 1.02 (0.90 to 1.17) 1.01 (0.89 to 1.16) 1.02 (0.89 to 1.16) 1.02 (0.90 to 1.17) 1.01 (0.88 to 1.15)
Frequently 1.78 (1.45 to 2.18) 1.53 (1.25 to 1.88) 1.51 (1.23 to 1.85) 1.52 (1.24 to 1.86) 1.53 (1.24 to 1.87) 1.50 (1.22 to 1.84)
I do not know 1.02 (0.77 to 1.35) 0.94 (0.71 to 1.24) 0.93 (0.71 to 1.23) 0.95 (0.72 to 1.25) 0.94 (0.71 to 1.24) 0.94 (0.71 to 1.24)
Men (n=1315)
No 1.00 1.00 1.00 1.00 1.00 1.00
Sometimes 1.38 (1.02 to 1.86) 1.27 (0.94 to 1.71) 1.25 (0.92 to 1.69) 1.25 (0.92 to 1.69) 1.22 (0.90 to 1.65) 1.18 (0.87 to 1.59)
Frequently 2.32 (1.49 to 3.61) 1.92 (1.23 to 2.99) 1.67 (1.05 to 2.67) 1.94 (1.24 to 3.02) 1.89 (1.21 to 2.94) 1.65 (1.04 to 2.60)
I do not know 1.35 (0.73 to 2.48) 1.16 (0.63 to 2.15) 1.10 (0.60 to 2.04) 1.16 (0.63 to 2.13) 1.11 (0.60 to 2.04) 1.03 (0.56 to 1.91)
Model 1, age adjusted for; Model 2, age and previous psychotropic medication adjusted for; Model 3, age, previous psychotropic medication and childhood bullying adjusted for; Model 4, age,
previous psychotropic medication and occupational class adjusted for; Model 5, age, previous psychotropic medication and body mass index adjusted for; and Model 6, all variables in Models
1–5 adjusted for (full model).
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have been varied and objective measurement such as
register-based psychotropic medication has been lacking.
The ﬁndings of our prospective study using objective
data on psychotropic medication avoid reporting bias for
medication. Our ﬁndings conﬁrm in a longitudinal
design the previous cross-sectional and self-reported
ﬁndings on the signiﬁcance of workplace bullying to
employee mental health problems.
The included covariates had but minor contributions
to the examined associations. For example, childhood
bullying could have been expected to contribute to the
association between current bullying and psychotropic
medication, but its contributions were minor. Of those
reporting childhood bullying, 11% reported that they
were currently bullied as well. It has also been shown
earlier that only some of those who have been bullied at
school are bullied at workplace as well.21 However, as the
validity of retrospective reports on bullying is limited,30
this information does not fully rule out even stronger
effects of earlier bullying on the examined associations.
To further conﬁrm the possible effects, we excluded
those reporting childhood bullying from the analyses
(n=459), but the associations remained or were slightly
strengthened (data not shown). These sensitivity analyses
suggest that the data are not selective to any larger
extent and that the results do not reﬂect sensitivity to
the exposure.
Although obesity tends to be stigmatising, bullied
employees likely have only slightly higher body mass
index.15 Obesity is also connected to mental health pro-
blems.31 Nevertheless, body mass index had negligible
effects on the examined associations in this study. It is
possible that in younger or other type of employee
cohorts than our middle-aged public sector cohort,
obesity might be a more sensitive issue. Alternatively, the
results suggest that workplace bullying and its harmful
consequences for mental health are unaccounted by
relative weight, and are equally found across bullied
employees independent of their body weight. In add-
ition, we conducted sensitivity analyses adjusting for
various other potential confounders related to mental
health such as alcohol and smoking, but the results
remained unaffected (data not shown). However, it
cannot be ruled out that unmeasured covariates affected
the ﬁndings. For example, negative life events during
the follow-up, independent of earlier bullying, might
result to anxiety, depression and other mental health
problems leading to psychotropic medication.
Psychotropic medication before baseline was adjusted
for in our analyses to control for the contribution of
workplace bullying to psychotropic medication inde-
pendent of prior medication, which strongly predicted
subsequent medication (data not shown). Sensitivity ana-
lyses were conducted excluding all those who had had
any psychotropic medication before the baseline but the
results were similar to those after adjusting for prior
medication. To avoid any selection by covariates and
redundant loss of data, we retained the full sample. To
further control for potential selection and confounding,
and in particular the effects of earlier psychotropic
medication on workplace bullying at baseline and psy-
chotropic medication at follow-up, marginal structural
equation models were ﬁtted.32 33 The inverse probability
weights to ﬁt marginal structural models in a point treat-
ment situation was used for multinomial workplace
bullying and observing bullying at workplace.34 Weights
were calculated using sex, age, previous psychotropic
medication, childhood bullying and BMI as predictors.
The results remained unaffected or were even slightly
strengthened in these analyses, suggesting that selection
and confounding are unlikely to cause major bias to the
ﬁndings of this study. Nonetheless, previous prospective
studies have found bidirectional associations between
bullying and mental health suggesting that reverse caus-
ation cannot be excluded.2 14 Thus, while bullying
might contribute to mental health problems, those suf-
fering from mental problems might be more likely to be
bullied or perceive bullying.
Strengths and weaknesses
Some further weaknesses of this study need to be acknowl-
edged. First, our measures for bullying were based on
single questions. We lacked information about the speciﬁc
time frame, duration, intensity and number of episodes of
bullying. The associations might be stronger for more per-
sistent, frequent and intense bullying.7 However, in a cross-
sectional study, self-reported use of sedatives and hypnotics
was not signiﬁcantly associated with the duration, history
or frequency of bullying.1 Bullying is also likely to be
remembered and even single episodes could, therefore,
have long-lasting effects. Second, negative affectivity has
been suggested as a mediator of the association between
bullying and mental symptoms.35 We were unable to
control for such reporting tendency, but its effects are
likely minor in our study where the outcome was derived
from objective register data. Third, bullying is a sensitive
issue that may be under-reported in surveys. To the extent
that this holds for our study, the results are likely conserva-
tive. Under-reporting or hiding might also explain why
reporting ‘could not say’ to questions on bullying had
some associations with psychotropic medication. Fourth,
as only the middle-aged employees from the City of
Helsinki, Finland, were included, the results may not be
directly generalised to other age groups, cohorts or sector
of employment. However, there is no particular reason to
assume that the associations between workplace bullying
and subsequent psychotropic medication would be speciﬁc
to the current setting. As earlier cross-sectional studies
have already shown that workplace bullying is associated
with self-reported psychotropic medication,1 8–10 26 28 29
this further suggests that the results probably could apply
to other employed groups, too. Finally, a long follow-up
period might dilute the ﬁndings and changes over the
follow-up might affect our ﬁndings. However, as we exam-
ined the time until the ﬁrst purchase of psychotropic
medication after baseline, and the purchases of
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medication took place mostly before the end of the 5-year
follow-up, the third factors are unlikely to have affected
our results to any larger extent.
The strength of this study was large and prospective
cohort including register-data linkage on psychotropic
medication. While previous studies have mainly been cross-
sectional and relied on self-reports of one or few medica-
tion groups, our study sheds light on the signiﬁcance of
workplace bullying to objectively measured psychotropic
medication and thereby medically conﬁrmed mental
health problems more generally. Moreover, we were able to
control for various key covariates, and thus our results
showed associations of bullying with psychotropic medica-
tion independent of age, prior medication, childhood
exposures, occupational class and body mass index.
CONCLUSIONS
Our study showed that workplace bullying is associated
with subsequent psychotropic medication based on
objective register data reﬂecting medically conﬁrmed
mental health problems. These associations were found
among both women and men. In addition to current
workplace bullying, also earlier bullying and observing
bullying were associated with psychotropic medication.
Workplace bullying needs to be tackled proactively in an
effective way to prevent its adverse consequences for
mental health.
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